The timeline for adjusting dosage can vary depending on individual factors such as BMI , overall health, and response to treatment
Taking a dose too early may slightly increase the risk of side effects such as nausea, vomiting, or abdominal discomfort, but is unlikely to affect the overall effectiveness of treatment
Matching was performed using MatchIt (v
Effects of Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide on Cardiovascular and Renal Outcomes Across Body Mass Index Categories in Type 2 Diabetes: Results of the LEADER and SUSTAIN 6 Trials
[2] If youd like to learn more about off-label prescribing and whether it may be appropriate for you, our MedExpress clinicians can assess your individual treatment history, current medication and weight loss goals to help determine the safest option
Ongoing clinical success, regulatory submissions, and backing by Eli Lilly further drive rapid market growth, making Orforglipron a leading therapy in both obesity management and type 2 diabetes treatment